Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

出版年份 2014 全文链接

标题

作者

关键词

Blood pressure, Body weight, Empagliflozin, Glycemic control, Macrovascular, Microvascular, SGLT2 inhibitor, Type 2 diabetes

出版物

Volume 13, Issue 1, Pages 102

出版商

Springer Nature

发表日期

2014-06-19

DOI

10.1186/1475-2840-13-102

联系作者

Explore over 38,000 international journals covering a vast array of academic fields.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started